Tokyo, July 19, 2006 (JCN) - Trans Genic, a biotech company specializing in genome function research, and the Kumamoto Techno Industrial foundation have concluded an exclusive license agreement on anti-HIV antibodies PCT/JP2004/003046. The partners have produced a monoclonal antibody with a high level of neutralization activity against HIV as part of a therapeutic drug for AIDS.
